Empirico uses proprietary platforms to discover and develop siRNA therapeutics that mimic protective human genetic variants, enabling precise modulation of disease‑relevant genes.
Funding
Funding not disclosed
Founders
Product
Problem
Many common diseases lack effective treatments that target the underlying genetic mechanisms, and developing precision medicines that safely modulate disease‑relevant genes is technically challenging.
Solution
Empirico applies its proprietary technology platforms to discover and develop small‑interfering RNA (siRNA) therapeutics that replicate the protective effects of naturally occurring human genetic variants. By integrating deep human genetics analysis, advanced siRNA chemistry, and data‑driven target validation, the company creates a pipeline of differentiated candidates for diseases with unmet medical needs. Strategic licensing and development partnerships with pharmaceutical companies accelerate the translation of these precision medicines into clinical programs, leveraging partner resources for manufacturing, regulatory, and commercialization pathways.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to license or co‑develop precision siRNA therapeutics for common diseases with high unmet need.
Features
- Proprietary discovery platform that identifies beneficial genetic variants and selects corresponding gene targets for siRNA intervention
- Optimized siRNA chemistry enabling high potency, specificity, and favorable safety profiles for in vivo applications
- Integrated data‑science workflow that combines genomics, transcriptomics, and phenotypic data to prioritize and de‑risk targets
- Flexible partnership model allowing pharma collaborators to license candidates at various development stages
- Pipeline spanning preclinical and clinical‑stage programs focused on common diseases such as respiratory disorders